These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 15284486)
1. Adenovirus expressing a bioluminescence reporter gene and cMAGI cell assay for the detection of HIV-1. Borkow G; Lara HH; Ayash-Rashkovsky M; Tavor E; Lapidot A; Bentwich Z; Honigman A Virus Genes; 2004 Oct; 29(2):257-65. PubMed ID: 15284486 [TBL] [Abstract][Full Text] [Related]
2. A sensitive and versatile bioluminescence bioassay for HIV type 1 based on adenoviral vectors. Axelrod JH; Honigman A AIDS Res Hum Retroviruses; 1999 May; 15(8):759-67. PubMed ID: 10357471 [TBL] [Abstract][Full Text] [Related]
3. An adenovirus-based fluorescent reporter vector to identify and isolate HIV-infected cells. Richman L; Meylan PR; Munoz M; Pinaud S; Mirkovitch J J Virol Methods; 2002 Jan; 99(1-2):9-21. PubMed ID: 11684299 [TBL] [Abstract][Full Text] [Related]
4. Use of new T-cell-based cell lines expressing two luciferase reporters for accurately evaluating susceptibility to anti-human immunodeficiency virus type 1 drugs. Chiba-Mizutani T; Miura H; Matsuda M; Matsuda Z; Yokomaku Y; Miyauchi K; Nishizawa M; Yamamoto N; Sugiura W J Clin Microbiol; 2007 Feb; 45(2):477-87. PubMed ID: 17182760 [TBL] [Abstract][Full Text] [Related]
5. A sensitive reporter cell line for HIV-1 tat activity, HIV-1 inhibitors, and T cell activation effects. Aguilar-Cordova E; Chinen J; Donehower L; Lewis DE; Belmont JW AIDS Res Hum Retroviruses; 1994 Mar; 10(3):295-301. PubMed ID: 8018390 [TBL] [Abstract][Full Text] [Related]
6. Development of a dual reporter screening assay for distinguishing the inhibition of HIV Tat-mediated transcription from off-target effects. Shin Y; Choi BS; Kim KC; Kang C; Kim K; Yoon CH J Virol Methods; 2017 Nov; 249():1-9. PubMed ID: 28807730 [TBL] [Abstract][Full Text] [Related]
7. Anti-HIV effects of HIV vectors. Corbeau P; Wong-Staal F Virology; 1998 Apr; 243(2):268-74. PubMed ID: 9568026 [TBL] [Abstract][Full Text] [Related]
8. Improvement of HIV-1 and Human T Cell Lymphotropic Virus Type 1 Replication-Dependent Vectors via Optimization of Reporter Gene Reconstitution and Modification with Intronic Short Hairpin RNA. Shunaeva A; Potashnikova D; Pichugin A; Mishina A; Filatov A; Nikolaitchik O; Hu WS; Mazurov D J Virol; 2015 Oct; 89(20):10591-601. PubMed ID: 26269177 [TBL] [Abstract][Full Text] [Related]
9. Short communication: a single step assay for rapid evaluation of inhibitors targeting HIV type 1 Tat-mediated long terminal repeat transactivation. Chande AG; Baba M; Mukhopadhyaya R AIDS Res Hum Retroviruses; 2012 Aug; 28(8):902-6. PubMed ID: 21878060 [TBL] [Abstract][Full Text] [Related]
10. A nucleolar TAR decoy inhibitor of HIV-1 replication. Michienzi A; Li S; Zaia JA; Rossi JJ Proc Natl Acad Sci U S A; 2002 Oct; 99(22):14047-52. PubMed ID: 12376617 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV derived lentiviral production by TAR RNA binding domain of TAT protein. Mi MY; Zhang J; He Y Retrovirology; 2005 Nov; 2():71. PubMed ID: 16293193 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of human immunodeficiency virus type-1 by retroviral vectors expressing antisense-TAR. Chuah MK; VandenDriessche T; Chang HK; Ensoli B; Morgan RA Hum Gene Ther; 1994 Dec; 5(12):1467-75. PubMed ID: 7711139 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies. Mhashilkar AM; LaVecchio J; Eberhardt B; Porter-Brooks J; Boisot S; Dove JH; Pumphrey C; Li X; Weissmahr RN; Ring DB; Ramstedt U; Marasco WA Hum Gene Ther; 1999 Jun; 10(9):1453-67. PubMed ID: 10395371 [TBL] [Abstract][Full Text] [Related]
14. Bis-anthracycline antibiotics inhibit human immunodeficiency virus type 1 transcription. Kutsch O; Levy DN; Bates PJ; Decker J; Kosloff BR; Shaw GM; Priebe W; Benveniste EN Antimicrob Agents Chemother; 2004 May; 48(5):1652-63. PubMed ID: 15105117 [TBL] [Abstract][Full Text] [Related]
15. Potent and selective inhibition of Tat-dependent HIV-1 replication in chronically infected cells by a novel naphthalene derivative JTK-101. Wang X; Yamataka K; Okamoto M; Ikeda S; Baba M Antivir Chem Chemother; 2007; 18(4):201-11. PubMed ID: 17907378 [TBL] [Abstract][Full Text] [Related]
16. Antitat gene therapy: a candidate for late-stage AIDS patients. Lisziewicz J; Sun D; Lisziewicz A; Gallo RC Gene Ther; 1995 May; 2(3):218-22. PubMed ID: 7614253 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of novel quinoline derivatives as HIV-1 Tat-TAR interaction inhibitors. Chen S; Chen R; He M; Pang R; Tan Z; Yang M Bioorg Med Chem; 2009 Mar; 17(5):1948-56. PubMed ID: 19217787 [TBL] [Abstract][Full Text] [Related]
18. A structure-activity study of the inhibition of HIV-1 Tat-dependent trans-activation by mixmer 2'-O-methyl oligoribonucleotides containing locked nucleic acid (LNA), alpha-L-LNA, or 2'-thio-LNA residues. Arzumanov A; Stetsenko DA; Malakhov AD; Reichelt S; Sørensen MD; Babu BR; Wengel J; Gait MJ Oligonucleotides; 2003; 13(6):435-53. PubMed ID: 15025911 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat. Poznansky MC; Foxall R; Mhashilkar A; Coker R; Jones S; Ramstedt U; Marasco W Hum Gene Ther; 1998 Mar; 9(4):487-96. PubMed ID: 9525310 [TBL] [Abstract][Full Text] [Related]
20. Arginine methylation of the human immunodeficiency virus type 1 Tat protein by PRMT6 negatively affects Tat Interactions with both cyclin T1 and the Tat transactivation region. Xie B; Invernizzi CF; Richard S; Wainberg MA J Virol; 2007 Apr; 81(8):4226-34. PubMed ID: 17267505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]